NanoSphere Health Sciences has worked systematically with its intellectual property (IP) development team to achieve a strategic and strong patent position in the nanotechnology market with applications in each of our target verticals. The strategy is to protect and continuously build on our proprietary methodology. This delivery technology, was awarded the Frost and Sullivan 2018 Best Practices Award for Technological Innovation. The NanoSphere Delivery System™ (NDS) makes the nanoencapsulated ingredients more bioavailable and faster-acting, while also reducing adverse effects by delivering precise doses in smart nanoparticles to target sites.
U.S. Patent No. 9,925,149
Nanoparticle Compositions and Methods as Carriers of Nutraceutical Factors Across Cell Membranes and Biological Barriers
This patent claims and protects NanoSphere Health’s core technology for the formation and manufacturing of an improved lipid structured nanoparticle, which is the NanoSphere Delivery System (NDS). The patent also extends to 16 forms of lipid nanoparticles and can be applied across a variety of healthcare sectors for vastly improved delivery.
U.S. Patent 10,028,919 B2
Lipid Nanoparticle Compositions and Methods as Carriers of Cannabinoids in Standardized Precision-Metered Dosage Forms
This patent claims and protects NanoSphere’s NDS for phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid two-fold to eight-fold; decreases the dose of cannabinoids two-fold to eight-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enables more efficacious cannabinoid therapy.
CDN Patent 2,970,917
Methods of Treating Inflammatory Disorders and Global Inflammation with Compositions Comprising Phospholipid Nanoparticle Encapsulations of NSAIDs and holds the equivalent U.S. patent-pending US-2018-0055782-A1
This patent claims and protects NanoSphere’s NDS for phospholipid nanoparticle compositions of NSAIDs formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of NSAIDs; yielding an increase NSAID transport across hydrophobic mucosa; increasing the bioavailability of the NSAID two-fold to ten-fold; decreasing the dose of NSAIDs two-fold to ten-fold less than an amount of NSAID needed to illicit the same therapeutic effect compared to standard NSAID pills and capsules currently sold; where the phospholipids in the nanoparticle structure reduce or eliminate pathogenic effects of NSAIDs; and enable safe, daily, long term and more efficacious NSAID therapy and treatment and prevention of inflammatory disorders and global inflammation.
NHS also holds trade secrets on the manufacturing processes. NHS uses the most advanced technologies from a multiple of scientific disciplines to manufacture their products. It is in the best interest of NHS that the process is held secret, as it provides practical protection against infringement and is less burdensome than relying on legal defense of patent rights alone. Our manufacturing process applies across each of our seven verticals.